Published in Blood Weekly, March 3rd, 1997
"Our drug discovery strategy capitalizes on Alpha-Beta's core carbohydrate technology and on our expertise in infectious disease," said Spiros Jamas, Sc.D., Alpha-Beta. "MycoTox possesses innovative technology that will enable us to accelerate the discovery of new antifungal drugs."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.